Working… Menu

Apixaban for Extended Anticoagulation (APIDULCIS) (APIDULCIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03678506
Recruitment Status : Recruiting
First Posted : September 19, 2018
Last Update Posted : March 19, 2021
Information provided by (Responsible Party):
Arianna Anticoagulazione Foundation

Brief Summary:
The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients at high risk of recurrence (with altered D-dimer test), who had received anticoagulation (whatever the drug used) for 12-15 months after the first episode of thrombosis, will be treated with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.

Condition or disease Intervention/treatment Phase
Venous Thromboembolism Anticoagulants Drug: Apixaban Phase 4

Detailed Description:
This prospective cohort study aims to assess the efficacy and safety of a management procedure to decide on giving or not an extended anticoagulation (administering apixaban 2 2.5 mg twice daily ) to outpatients with a single episode of proximal deep vein thrombosis of the lower limbs and/or pulmonary embolism who had received 12-15 months of anticoagulation (whatever the anticoagulant drug used). The study seeks to assess whether a management procedure involving D-dimer testing assessment can identify a subset of subjects at low risk of recurrence in whom an extended anticoagulation can be safely avoided.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1200 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The patients included in the study will receive a serial determination of D-dimer assay (a maximum of four determinations in case of negative results).The D-dimer measurements should be performed at the moment of patient screening, when patients still assume their anticoagulant treatment (T0), at 15±2 days (T1), 30±4 days (T2), and 60±5 (T3) days after their anticoagulant treatment has been stopped. At the first positive D-dimer result patients resume anticoagulation with apixaban 2.5 mg bis in die for the next 18 months. Patients with negative D-Dimer results at all determinations stop anticoagulation definitely and will followed up for the next 18 months.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: APIDULCIS: Extended Anticoagulation With Low-dose Apixaban After a Standard Course Anticoagulation in Patients With a First Venous Thromboembolism Who Have Positive D-dimer
Actual Study Start Date : August 16, 2018
Estimated Primary Completion Date : October 30, 2021
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Apixaban

Arm Intervention/treatment
Experimental: Positive D-Dimer
At the first positive D-dimer results (during anticoagulation or after its temporary withdrawal) the patients are invited to assume Eliquis (apixaban) 2.5 mg twice daily, and continue this therapy for the following 18 months.
Drug: Apixaban
Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
Other Name: Apixaban and positive d-dimer

No Intervention: Negative D-Dimer
Patients with persistently negative results at the four serial D-dimer measurements, stay definitively without anticoagulation and discouraged to resume any antithrombotic drug for secondary VTE prevention.

Primary Outcome Measures :
  1. Number and rate of patients with confirmed recurrent VTE and VTE-related death (efficacy). [ Time Frame: From date of enrollment until the date of first documented event assessed up to 18 months ]
    The occurrence of proximal deep vein thrombosis with or without pulmonary embolism (new or recurrent episode) wil be recorded in all patients

  2. Number and rate of major Bleeding events (defined according to International Society on Thrombosis and Haemostasis guidelines (safety) [ Time Frame: From date of enrollment until the date of first documented event assessed up to18 months ]
    Fatal bleeding; intracranial; intraspinal; intraocular; pericardial; intra-articular; intramuscular with compartment syndrome; retroperitoneal,; acute clinically overt bleeding will be recorded in all patients

Secondary Outcome Measures :
  1. Number of and rate of thromboembolic events [ Time Frame: From date of enrollment until the date of first documented event assessed up to 18 months ]
    Transient ischemic attack (TIA), Stroke, Myocardial infarction will be recorded in all patients

  2. Presence of severe post-thrombotic syndrome according to Villalta Score [ Time Frame: 18 months ]
    Patient with deep vein thrombosis as index event will be evaluated, at the and of follow-up, applying Villalta score, commonly used to diagnose post-thrombotic syndrome in the subacute phase of thrombosis. The presence of venous ulcer of the leg or a score > of 15 points indicate the occurrence of severe post-thrombotic syndrome. The maximum score is 33. The score from 5 to 9 points indicate mild post-thrombotic syndrome and from 10 to 15 points indicate moderate post-thrombotic syndrome

  3. Number and rate of non major bleeding complications [ Time Frame: From date of enrollment until the date of first documented event assessed up to18 months ]
    In all patients will be recorded any sign or symptom of hemorrhage that does not fit the criteria for the definition of major bleeding but does meet at least one of the following criteria: 1)requiring medical intervention by a healthcare professional; 2) leading to hospitalization or increased level of care;3) prompting a face to face evaluation

  4. Number and rate of dead patients (overall mortality) [ Time Frame: From date of enrollment until the date of first documented event assessed up to 18 months ]
    VTE-related death; cardiovascular related-death; bleeding-related death; death for: cancer, infectious disease and unknown cause; sudden death will be recorded in all patients

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • First unprovoked Venous Thromboembolic Event
  • Venous Thromboembolic events associated with one or more risk factors that are no longer present
  • Age older than 18 or younger than 75 years
  • Capacity to give written informed consent

Exclusion Criteria:

  • A) Exclusion criteria regarding the index event
  • Events usually associated with low risk of recurrence
  • Deep vein thrombosis/ Pulmonary embolism occurred within 3 months from major surgery or major trauma
  • Isolated Distal deep vein thrombosis (thrombosis of calf veins)
  • Events associated with a very high risk of recurrence or occurrence of life-threatening recurrent events

    • Pulmonary Embolism episode with shock or life-threatening
    • Isolated pulmonary embolism with a systolic pulmonary artery pressure > 60 mmHg at presentation
    • Deep vein thrombosis/ Pulmonary embolism associated with active cancer, antiphospholipid syndrome or long-standing medical illnesses
    • More than one idiopathic event
  • Index venous thromboembolic event in different sites than deep veins of the lower limbs or pulmonary arteries

B) Exclusion criteria present at the moment of patients' screening:

  • Age younger than 18 or older than 75 years
  • More documented unprovoked venous thromboembolic episodes
  • Pregnancy or puerperium
  • Severe post-thrombotic syndrome (≥ 15 points at the Villalta score)
  • Solid neoplasia or blood disease in active phase or requiring chemotherapy/radiotherapy
  • All the clinical conditions requiring prolonged treatment with Low Molecular Weight Heparin
  • Presence of overt, active chronic diseases (i.e. inflammatory bowel disease)
  • Known serious thrombophilic alterations:

    • deficiencies of natural anticoagulants (Antithrombin, Protein C, Protein S)
    • homozygosity for Factor V Leiden or Factor II G20210A mutations
    • double heterozygosity
  • Presence of antiphospholipid syndrome
  • Presence of vein cava filter
  • Concomitant conditions (such as atrial fibrillation) requiring indefinite anticoagulation
  • Severe cardio-respiratory insufficiency (NYHA 3 or 4)
  • Any absolute contraindications to anticoagulation treatment
  • Any other contraindications to Apixaban as per local SmPC
  • Life expectancy shorter than 1 year
  • Refuse interruption of anticoagulation to perform serial D-dimer assessment
  • Geographically inaccessible location
  • Inability or refusal to give consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03678506

Layout table for location contacts
Contact: Cristina Legnani, BSc, PhD 0039 051 2812339
Contact: Emilia Antonucci, CR 0039 051 4291116

Layout table for location information
Daniela Poli Recruiting
Firenze, Italy, 50134
Sponsors and Collaborators
Arianna Anticoagulazione Foundation
Layout table for investigator information
Study Director: Daniela Poli, MD Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
  Study Documents (Full-Text)

Documents provided by Arianna Anticoagulazione Foundation:
Study Protocol  [PDF] January 16, 2018
Statistical Analysis Plan  [PDF] January 16, 2018

Layout table for additonal information
Responsible Party: Arianna Anticoagulazione Foundation Identifier: NCT03678506    
Other Study ID Numbers: FAA I1. 7-2017 (APIDULCIS)
2017 002340 32 ( EudraCT Number )
First Posted: September 19, 2018    Key Record Dates
Last Update Posted: March 19, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All collected data will be shared
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: The data will be available after the publication of global results of the study or after 18 months from the enrollment of the last patients
Access Criteria: Data access requests will be reviewed by the Scientific board of the study.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Arianna Anticoagulazione Foundation:
Venous thromboembolism
Extended treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action